Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.
Clinical trial NCT05838066 · RECRUITING
Trial details
- NCT number
- NCT05838066
- Sponsor
- Shanghai JMT-Bio Inc.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-23
- Primary completion
- 2025-07-31
- Enrollment
- 880
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.